1 Aug

Eli Lilly’s Q2 2018 Earnings: New Products

WRITTEN BY Mike Benson

New products portfolio

Eli Lilly & Co.’s (LLY) new products portfolio includes several drugs that have been launched since 2014. This portfolio includes Olumiant, Lartruvo, Taltz, Jardiance, Trulicity, Cyramza, Basaglar, and Verzenio. The chart below compares the revenues for LLY’s new products since the first quarter of 2017.

Eli Lilly’s Q2 2018 Earnings: New Products

Basaglar

Basaglar, an insulin glargine injection, reported 133.0% YoY (year-over-year) revenue growth to ~$201.8 million during the second quarter. Its revenues in the second quarter of 2017 totaled ~$86.6 million. This growth was driven by an increase in US sales to ~$156.5 million and nearly flat international sales of ~$45.3 million.

Jardiance

Jardiance, a part of the Boehringer Ingelheim and Eli Lilly’s diabetes alliance, reported revenues of ~$147.2 million during the second quarter. This represents 43.0% growth in YoY revenues compared to revenues of $103.2 million during the second quarter of 2017. The drug’s US sales increased 28.0%, and its international sales increased 70.0% in the quarter.

Taltz

Taltz reported revenues of $220.1 million during the second quarter, representing 59.0% growth in YoY revenues compared to $138.7 million during the second quarter of 2017. The drug’s US sales totaled $174.0 million, and its international sales totaled $46.0 million during the quarter.

Trulicity

Trulicity reported revenues of $779.8 million during the second quarter, representing 62.0% growth in YoY revenues compared to $480.2 million during the second quarter of 2017. The drug’s US sales increased ~61.0%, and its international sales rose ~69.0% during the quarter.

Verzenio

Verzenio is a new oncology drug for the treatment of HR+, HER2- advanced breast cancer, or metastatic breast cancer. Verzenio was launched in the US markets in the fourth quarter of 2017. Verzenio reported revenues of $57.7 million during the second quarter.

We discussed the performance of Cyramza and Lartruvo in Part 5 of this series.

The VanEck Vectors Pharmaceutical ETF (PPH) holds 4.8% of its total investments in Eli Lilly (LLY), 5.4% in Novartis AG (NVS), 5.4% in Sanofi (SNY), and 5.2% in Johnson & Johnson (JNJ).

Latest articles

Tortoise Capital Advisors bought 9.5 million Kinder Morgan shares in Q3. That was the biggest addition among the company’s top 10 institutional investors.

Although near-term weakness exists in the cannabis stocks, we expect Cannabis 2.0 products or cannabis-derived products could act as a catalyst.

The US, Saudi Arabia, and Russia are the world’s top three crude oil producers. Let’s take a look at the world’s top oil players by production volumes.

Tesla’s Model Y is gearing up to enter the EV market next summer. Ford heated up this space with its announcement of the Mustang Mach-E launch in late 2020.

Yesterday, Comcast (CMCSA) rose 0.5% and closed at $44.81, with a market capitalization of $203.9 billion. But can you expect a further rise?

Advanced Micro Devices (AMD) is one of the best-performing semiconductor stocks of 2019, beating 100% year-to-date growth.